READTHROUGH ACETYLCHOLINESTERASE (ACHE-R) FOR TREATING OR PREVENTING PARKINSON'S DISEASE
A method of treating or preventing Parkinson's disease in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of AChE-R, wherein the AChE-R is devoid of an N-terminal extension. An additional method of treating or preventing Parkinson's disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of AChE-R, wherein the AChE-R comprises a modification for increasing bioavailability.
1 . A method of treating or preventing Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an acetylcholine esterase-R (AChE-R) polypeptide, wherein the AChE-R polypeptide is devoid of an N-terminal extension to thereby treat the Parkinson's disease in the subject.
2 . The method of claim 1 , wherein said AChE-R polypeptide comprises a recombinant AChE-R polypeptide.
3 . The method of claim 2 , wherein said recombinant AChE-R is plant produced AChE-R.
4 . The method of claim 1 , wherein said AChE-R polypeptide has an amino acid sequence as set forth in SEQ ID NOs. 1 and 3.
5 . The method of claim 1 , wherein said administering is peripherally administering.
6 . A method of treating or preventing Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ACNE-R polypeptide, wherein the AChE-R polypeptide comprises a modification for increasing bioavailability, thereby treating the Parkinson's disease in the subject.
7 . The method of claim 6 , wherein said AChE-R polypeptide is devoid of an N-terminal extension.
8 . The method of claim 6 , wherein said AChE-R polypeptide comprises an N-terminal extension.
9 . The method of claim 8 , wherein said N-terminal extension is at least 90% homologous to SEQ ID NO: 2.
10 . The method of claim 6 , wherein said AChE-R polypeptide comprises recombinant AChE-R.
11 . The method of claim 10 , wherein said recombinant AChE-R is plant produced AChE-R.
12 . The method of claim 6 , wherein said AChE-R polypeptide has an amino acid sequences as set forth in SEQ ID NOs. 1 and 3.
13 . The method of claim 6 , wherein said modification comprises attachment to a heterologous polypeptide.
14 . The method of claim 13 , wherein said heterologous polypeptide is selected from the group consisting of human serum albumin, immunoglobulin, and transferrin.
15 . The method of claim 14 , wherein said immunoglobulin comprises an Fc domain.
16 . The method of claim 6 , wherein said modification comprises attachment to a polymer.
17 . The method of claim 16 , wherein said polymer is selected from the group consisting of a polycationic polymer, a non-ionic water-soluble polymer, a polyether polymer and a biocompatible polymer.
18 . The method of claim 16 , wherein said polymer is poly(ethylene glycol).
19 . The method of claim 6 , wherein said administering is peripherally administering.